Nagasawa Daniel T, Choy Winward, Spasic Marko, Yew Andrew, Trang Andy, Garcia Heather M, Yang Isaac
UCLA Department of Neurological Surgery, University of California Los Angeles, Los Angeles, CA 90095-1761, USA.
Clin Neurol Neurosurg. 2013 Jul;115(7):1071-8. doi: 10.1016/j.clineuro.2012.10.026. Epub 2012 Dec 6.
While typically benign, epidermoid tumors upon rare occasion can undergo malignant transformation, which carries a poor prognosis. Here, we reviewed treatment strategies and analyzed outcomes for every case of malignant epidermoid tumor reported since its original description in 1912.
A comprehensive literature review identified all reported cases of malignant transformation of intracranial epidermoid tumor. Treatments were categorized as follows: palliative management, stereotactic radiosurgery (SRS), chemotherapy, and surgery plus multiple (2+) adjuvant therapies. Survival data of these groups were compared to treatment outcomes for patients receiving only surgical resection, as reported in our previous study.
We identified 58 cases of intracranial epidermoid tumor with malignant degeneration. Average survival regardless of therapy was 11.8 months. Mean survival outcomes for groups treated with palliative management, chemotherapy, SRS, and multiple postoperative adjuvant therapies were 5.3 months, 25.7 months, 29.2 months, and 36.3 months, respectively. Outcomes for the groups including SRS, chemotherapy, and multiple post-operative adjuvant therapies were statistically significant compared to surgical resection alone.
While there remains a lack of consensus regarding the best approach to the management of patients with malignant epidermoid tumors, our systematic analysis characterizes and confirms the added benefit of SRS, chemotherapy, and multimodal adjuvant therapies.
表皮样肿瘤通常为良性,但极少数情况下可发生恶性转化,预后较差。在此,我们回顾了治疗策略,并分析了自1912年首次描述以来报告的每例恶性表皮样肿瘤的治疗结果。
通过全面的文献综述,确定了所有报告的颅内表皮样肿瘤恶性转化病例。治疗方法分为以下几类:姑息治疗、立体定向放射外科(SRS)、化疗以及手术加多种(两种及以上)辅助治疗。将这些组的生存数据与我们之前研究中报告的仅接受手术切除患者的治疗结果进行比较。
我们确定了58例颅内表皮样肿瘤发生恶性退变的病例。无论采用何种治疗方法,平均生存期为11.8个月。接受姑息治疗、化疗、SRS以及多种术后辅助治疗的组的平均生存结果分别为5.3个月、25.7个月、29.2个月和36.3个月。与单纯手术切除相比,包括SRS、化疗和多种术后辅助治疗的组的结果具有统计学意义。
虽然对于恶性表皮样肿瘤患者的最佳治疗方法仍缺乏共识,但我们的系统分析描述并证实了SRS、化疗和多模式辅助治疗的附加益处。